Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough

Gefapixant is a P2X3‐receptor antagonist being developed for treatment of refractory or unexplained chronic cough. Four phase 1 studies were conducted in healthy participants that bridged the early‐phase gefapixant formulation (F01) to the phase 3 (F04A) and intended commercial (F04B) formulations....

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Pranav, Hussain, Azher, Ford, Anthony P., Smith, Steven, Nussbaum, Jesse C., Stoch, Aubrey, Iwamoto, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540877/
https://www.ncbi.nlm.nih.gov/pubmed/35510785
http://dx.doi.org/10.1002/cpdd.1105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540877/
https://www.ncbi.nlm.nih.gov/pubmed/35510785
http://dx.doi.org/10.1002/cpdd.1105

Ejemplares similares